Summary
- A total of 102 patients with primary brain tumors were included in the MTB-FR observational study, with 85% of patients undergoing successful tumor molecular profiling and multidisciplinary discussions for treatment recommendations.
- Biomarker-informed therapies were recommended for 71% of patients, with 32% of patients ultimately receiving the recommended targeted treatment.
- The study cohort was highly heterogeneous with 21 different brain tumor entities, spanning all CNS-WHO grades from 1 to 4.
- Tumor sequencing results revealed common gene alterations such as TP53, PTEN, and EGFR, with some cases leading to a revision of the initial diagnosis based on molecular profiling.
- Implemented biomarker-guided therapies resulted in a disease control rate of 50%, with 30% overall response rate, and an overall survival of 657 days after treatment implementation.
Researchers have conducted a study on patients with primary brain tumors to determine the effectiveness of personalized treatment based on the tumor’s molecular profile. The study included 102 patients with different types of brain tumors, with the majority being grade 4 glioblastomas.
The study involved analyzing the tumor samples to identify specific genetic mutations that could guide the treatment recommendations. The researchers found common mutations in genes like TP53, PTEN, and EGFR, which are known to play a role in brain tumors. They also detected fusion genes like NTRK and BRAF-KIAA1549, which can be targets for treatment.
Based on the molecular findings, the researchers recommended targeted therapies for 71% of the patients. These treatments included drugs that specifically target the genetic alterations found in the tumors. About 32% of the patients received the recommended treatments, with varying responses depending on the grade of the tumor and the type of evidence supporting the treatment recommendation.
The patients who received targeted treatments showed a disease control rate of 50% and an overall response rate of 30%. While some patients experienced adverse effects that required adjustments to the treatment, overall, the personalized treatments showed promising results. The patients who received targeted therapies had a median overall survival of 657 days, compared to 264 days for those who did not receive the recommended treatments.
Overall, the study highlights the importance of personalized treatment approaches based on the molecular characteristics of the tumors. By identifying specific genetic alterations and matching them with targeted therapies, researchers can improve treatment outcomes for patients with primary brain tumors.
Source link
Oncology, Neurology, Molecularly guided treatment, primary CNS tumors